Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase...
November 24 2020 - 4:15PM
Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global
provider of life science reagents and services to researchers and
biotech innovators, today announced the closing of its initial
public offering of 69,000,000 shares of Class A common stock,
including the full exercise of the underwriters’ option to purchase
up to 9,000,000 additional shares of Class A common stock, at a
public offering price of $27 per share. The aggregate gross
proceeds to Maravai from the offering were approximately
$1,863,000,000, before deducting underwriting discounts and
commissions and other offering expenses. All of the shares in the
offering were offered by Maravai. Maravai’s Class A common stock
began trading on the Nasdaq Global Select Market on November 20,
2020 under the symbol "MRVI."
Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted
as joint book-running managers for the offering. BofA Securities,
Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel
and KeyBanc Capital Markets also acted as joint book-running
managers, and Academy Securities, Loop Capital Markets, Penserra
Securities LLC and Tigress Financial Partners acted as co-managers
for the offering.
Perella Weinberg Partners L.P. served as capital markets advisor
to Maravai. Kirkland & Ellis LLP provided legal counsel to
Maravai and Davis Polk & Wardwell LLP provided legal counsel to
the underwriters.
A registration statement on Form S-1 relating to these
securities was filed with the U.S. Securities and Exchange
Commission (“SEC”) and became effective on November 19, 2020. The
offering was made only by means of a prospectus. A copy of the
final prospectus relating to the securities has been filed with the
SEC and may be obtained from: Morgan Stanley & Co. LLC,
Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014, or by email at prospectus@morganstanley.com;
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at
877-821-7388 or by email at Prospectus_Department@Jefferies.com; or
Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, NY 10282, by telephone
at 866-471-2526, by facsimile
at 212-902-9316 or
by email at prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, novel vaccines and
support research on human diseases through its portfolio of
companies and their proprietary capabilities and products.
Maravai’s companies are leaders in providing products and services
in the fields of nucleic acid synthesis, bioprocess impurity
detection and analysis, and protein labeling and detection to many
of the world's leading biopharmaceutical, vaccine, diagnostics, and
cell and gene therapy companies.
Investor and Media Contact
Sara Michelmore
MacDougall
+1 781-235-3060
maravai@macbiocom.com
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Apr 2023 to Apr 2024